Comparing GLP-1 drugs and mineralocorticoid blockers as fourth-choice treatments for hard-to-control high blood pressure in overweight or obese patients

The effectiveness of GLP-1 receptor agonists compared to mineralocorticoid receptor antagonists in treating resistant hypertension in individuals with overweight or obesity is being evaluated.

• Resistant hypertension frequently occurs in individuals with overweight or obesity.
• Mineralocorticoid receptor antagonists are the recommended treatment for resistant hypertension.
• Glucagon-like peptide-1 receptor agonists induce significant weight loss and may reduce cardiovascular and renal events.
• The potential of GLP-1 receptor agonists as an alternative treatment for resistant hypertension is currently unclear.

Simplified